Fröhlich, Tanja

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2016 | 2015 | 2014 | 2013 | 2011

2016

Meulendijks, D; Henricks, LM; Amstutz, Ursula; Fröhlich, Tanja; Largiadèr, Carlo Rodolfo; Beijnen, JH; de Boer, A; Deenen, MJ; Cats, A; Schellens, JHM (2016). Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International journal of cancer, 138(11), pp. 2752-2761. Wiley-Blackwell 10.1002/ijc.30014

2015

Fröhlich, Tanja; Amstutz, Ursula; Aebi, Stefan; Joerger, Markus; Largiadèr, Carlo Rodolfo (2015). Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. International journal of cancer, 136(3), pp. 730-739. Wiley-Blackwell 10.1002/ijc.29025

2014

Sistonen, Johanna; Büchel, Barbara; Fröhlich, Tanja; Kummer, Dominic; Fontana, Stefano; Joerger, Markus; van Kuilenburg, André B P; Largiadèr, Carlo Rodolfo (2014). Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics, 15(13), pp. 1653-1666. Future Medicine 10.2217/pgs.14.126

2013

Mueller, F; Büchel, B; Köberle, D; Schürch, Stefan; Pfister, B; Krähenbühl, St; Fröhlich, Tanja; Largiader, C R; Joerger, M (2013). Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer chemotherapy and pharmacology, 71(2), pp. 361-70. Berlin: Springer 10.1007/s00280-012-2018-4

2011

Amstutz, Ursula; Froehlich, Tanja K; Largiadèr, Carlo R (2011). Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics, 12(9), pp. 1321-36. London: Future Medicine 10.2217/PGS.11.72

Provide Feedback